A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Incyte Corporation
AbbVie
Pfizer
Takeda
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
AbbVie
Parabilis Medicines, Inc.
Pfizer
Seagen Inc.
Vividion Therapeutics, Inc.
Seagen Inc.
Summit Therapeutics
Vejle Hospital
University of Wisconsin, Madison
Amgen
Novartis
Revolution Medicines, Inc.
Hoffmann-La Roche
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Ono Pharmaceutical Co. Ltd
Tianjin Medical University Cancer Institute and Hospital
Eastern Cooperative Oncology Group
AstraZeneca
Chipscreen Biosciences, Ltd.
EMD Serono
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Multitude Therapeutics Inc.
Delcath Systems Inc.
Pfizer
Merck Sharp & Dohme LLC
BioNTech SE
Sun Yat-sen University
Neonc Technologies, Inc.
M.D. Anderson Cancer Center
Pfizer
AstraZeneca
Inspirna, Inc.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Gruppo Oncologico del Nord-Ovest
Genentech, Inc.
Roswell Park Cancer Institute
Hoffmann-La Roche
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Luye Pharma Group Ltd.
University of Wisconsin, Madison